Last Updated : May 15, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Trintellix | vortioxetine hydrobromide | Major depressive disorder (MDD), adults. | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo-Yervoy | nivolumab-ipilimumab | Malignant Pleural Mesothelioma (MPM) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Tecartus | brexucabtagene autoleucel | Mantle cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Brukinsa | zanubrutinib | Mantle cell lymphoma (MCL) | Do not reimburse | Complete | ||
| Imbruvica | Ibrutinib | Mantle Cell Lymphoma (relapsed/refractory) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Mvasi | Bevacizumab | mCRC NSCLC Biosimilar | N/A | Complete | ||
| Lonsurf | Trifluridine and Tipiracil | mCRC Resubmission | Do not reimburse | Complete | ||
| Mifegymiso | Mifepristone and misoprostol | Medical termination of pregnancy (gestational age up to 49 days) | Reimburse | Complete | ||
| Mifegymiso | Mifepristone and misoprostol | Medical termination of pregnancy (gestational age up to 49 days) | Withdrawn | |||
| Caprelsa | Vandetanib | Medullary Thyroid Cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 15, 2024